Copyright
©The Author(s) 2018.
World J Diabetes. Jan 15, 2018; 9(1): 1-24
Published online Jan 15, 2018. doi: 10.4239/wjd.v9.i1.1
Published online Jan 15, 2018. doi: 10.4239/wjd.v9.i1.1
Table 1 Cardiac autonomic neuropathy in type 1 and type 2 diabetes mellitus: Differences in relation to risk factors and natural history[21]
| Risk factors | Type 1 DM | Type 2 DM |
| Age | + | + |
| Gender (female) | + | - |
| Obesity | - | + |
| Hyperinsulinemia | NA | + |
| Duration of DM | ++ | ++ |
| Smoking | + | + |
| HbA1c | ++ | ++ |
| Hypertension | ++ | + |
| Retinopathy | ++ | + |
| Hypertriglyceridemia | + | + |
| Classical DPN | ++ | ++ |
| Microalbuminuria | ++ | ++ |
| Dyslipoproteinemia (> LDL and < HDL | + | (+) |
| Prevalence at diagnosis of DM | 7.70% | 5% |
| Prevalence after 10 yr | 38% | 65% |
| Prevalence (random) | 25% | 34% |
| Cardiovascular system | Peripheral vascular function |
| Perioperative unstability | ↑ Peripheral blood flow and warm skin |
| Resting tachycardia | ↑ Arteriovenous shunting and swollen veins |
| Loss of reflex heart rate variations | ↑ Venous pressure |
| Hypertension | Leg and foot oedema |
| Exercise intolerance | Loss of protective cutaneous vasomotor reflexes |
| Orthostatic hypotension | Loss of venoarteriolar reflex with microvascular damage |
| Postprandial hypotension | ↑ Transcapillary leakage of macromolecules |
| Silent myocardial ischaemia | ↑ Medial arterial calcification |
| Left ventricular dysfunction and hypertrophy | - |
| QT interval prolongation | - |
| Impaired baroreflex sensitivity | - |
| Non-dipping, reverse dipping | - |
| Sympathovagal imbalance | - |
| Dysregulation of cerebral circulation | - |
| ↓ Sympathetically mediated vasodilation of coronary vessels | - |
| ↑ Arterial stiffness | - |
Table 3 Symptoms and signs associated with diabetic cardiovascular autonomic neuropathy[39]
| Cardiovascular autonomic neuropathy | |
| Resting tachycardia | |
| Abnormal blood pressure regulation | Nondipping |
| Reverse dipping | |
| Orthostatic hypotension (all with standing) | Light-headedness |
| Weakness | |
| Faintness | |
| Visual impairment | |
| Syncope | |
| Orthostatic tachycardia or bradycardia and chronotropic incompetence (all with standing) | Light-headedness |
| Weakness | |
| Faintness | |
| Dizziness | |
| Visual impairment | |
| Syncope | |
| Exercise intolerance | |
| Test | Technique | Normal response and values |
| Beat-to-beat HRV | With the patient at rest and supine, heart rate is monitored by ECG while the patient breathes in and out at 6 breaths per minute, paced by a metronome or similar device | A difference in HR of > 15 beats per minute is normal and < 10 beats per minute is abnormal. The lowest normal value for the expiration-to inspiration ratio of the R-R interval decreases with age: age 20-24 yr, 1.17; 25-29, 1.15; 30-34, 1.13; 35-39, 1.12; 40-44, 1.10; 45-49, 1.08; 50-54, 1.07; 55-59, 1.06; 60-64, 1.04; 65-69, 1.03; and 70-75, 1.02 |
| Heart rate response to standing | During continuous ECG monitoring, the R-R interval is measured at beats 15 and 30 after standing | Normally, a tachycardia is followed by reflex bradycardia. The 30:15 ratio should be > 1.03, borderline 1.01-1.03 |
| Heart rate response to the valsalva maneuver | The subject forcibly exhales into the mouthpiece of a manometer to 40 mmHg for 15 s during ECG monitoring | Healthy subjects develop tachycardia and peripheral vasoconstriction during strain and an overshoot bradycardia and rise in BP with release. The normal ratio of longest R-R to shortest R-R is > 1.2, borderline 1.11-1.2 |
| Systolic blood pressure response to standing | Systolic BP is measured in the supine subject. The patient stands and the systolic BP is measured after 2 min | Normal response is a fall of < 10 mmHg, borderline fall is a fall of 10-29 mmHg and abnormal fall is a decrease of > 30 mmHg |
| Diastolic blood pressure response to isometric exercise | The subject squeezes a handgrip dynamometer to establish a maximum. Grip is then squeezed at 30% maximum for 5 min | The normal response for diastolic BP is a rise of > 16 mmHg in the other arm, borderline 11-15 mmHg |
Table 5 Normal, borderline and abnormal values in tests of cardiovascular autonomic function[27]
| Normal | Borderline | Abnormal | |
| Tests reflecting mainly parasympathetic function | |||
| Heart rate response to Valsalva Manoeuvre (Valsalva ratio) | ≥ 1.21 | 1.11–1.20 | ≤ 1.10 |
| Heart rate (R-R interval) variation | ≥ 15 beats/min | 11–14 beats/min | ≤ 10 beats/min |
| During deep breathing (maximum-minimum heart rate) immediate heart rate response to standing (30:15 ratio) | ≥ 1.04 | 1.01-1.03 | ≤ 1.00 |
| Tests reflecting mainly sympathetic function | |||
| Blood pressure response to standing (fall in systolic blood mmHg mmHg mmHg pressure) | ≤ 10 | 11–29 | ≥ 30 |
| Blood pressure response to sustained handgrip (increase in diastolic blood pressure | ≥ 16 mmHg | 11–15 mmHg | ≤ 10 mmHg |
| Symptoms | Signs/diagnostic tests | Differential workup | |
| Resting tachycardia | Palpitations could be asymptomatic | Clinical exam: Resting heart rate > 100 bpm | Anemia hyperthyroidism fever |
| CVD (atrial fibrillation, | |||
| flutter, other) | |||
| Dehydration | |||
| Adrenal insufficiency | |||
| Some medications | |||
| Smoking, alcohol, caffeine | |||
| Recreational drugs (cocaine, amphetamines, methamphetamine, mephedrone) | |||
| Orthostatic hypotension | Light-headedness | Clinical exam: A reduction of > 20 mmHg in the systolic blood pressure or > 10 mmHg in diastolic blood pressure | Adrenal insufficiency |
| Weakness | Intravascular volume depletion | ||
| Faintness | Blood loss/acute anemia | ||
| Visual impairment | Dehydration | ||
| Syncope | Pregnancy/postpartum | ||
| CVD | |||
| Alcohol | |||
| Medication | |||
| Antiadrenergics | |||
| Antianginals | |||
| Antiarrhythmics | |||
| Anticholinergics | |||
| Diuretics | |||
| ACE inhibitors/angiotensin receptor blocker | |||
| Narcotics | |||
| Neuroleptics | |||
| Sedatives |
Table 7 Differential diagnosis of diabetic neuropathies[39]
| Metabolic disease | Thyroid disease (common) |
| Renal disease | |
| Systemic disease | Systemic vasculitis |
| Nonsystemic vasculitis | |
| Paraproteinemia (common) | |
| Amyloidosis | |
| Infectious | Human immunodeficiency virus |
| Hepatitis B | |
| Lyme | |
| Inflammatory | Chronic inflammatory demyelinating polyradiculoneuropathy |
| Nutritional | B12 |
| Postgastroplasty | |
| Pyridoxine | |
| Thiamine | |
| Tocopherol | |
| Industrial agents, drugs, and metals | |
| Industrial agents | |
| Acrylamide | |
| Organophosphorous agents | |
| Drugs | Alcohol |
| Amiodarone | |
| Colchicine | |
| Dapsone | |
| Vinka alkaloids | |
| Metals | Platinum |
| Taxol | |
| Arsenic | |
| Mercury | |
| Hereditary | Hereditary motor, sensory, and autonomic neuropathies |
- Citation: Serhiyenko VA, Serhiyenko AA. Cardiac autonomic neuropathy: Risk factors, diagnosis and treatment. World J Diabetes 2018; 9(1): 1-24
- URL: https://www.wjgnet.com/1948-9358/full/v9/i1/1.htm
- DOI: https://dx.doi.org/10.4239/wjd.v9.i1.1
